Fran Visit 2 - 56-year-old Woman with Worsening Pulmonary Function
| Title: | Fran Visit 2 - 56-year-old Woman with Worsening Pulmonary Function |
| Topic: | Pulmonary Disease |
| Relevant Terms: | AATD, COPD, Emphysema, Pulmonary Function |
| Primary Audience: | Internal medicine physicians, Primary Care Physicians, Pulmonologists |
| Launch Date: | 18-Aug-09 |
| Credits: | 0.5 AMA PRA Category 1 Credit™ |
| Expiration Date: | The accreditation for this activity has expired. |
Learning Objectives
After completion of this activity, participants should be better able to:
- Define the parameters of pulmonary disease progression and identify essential diagnostic studies
- Evaluate various bridging strategies for patients awaiting lung transplantation
- Explain the rationale for augmentation therapy administered to patients who have undergone lung transplantation
Faculty
James K. Stoller, MD, MS
Jean Wall Bennett Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Head, Cleveland Clinic Respiratory Therapy
Chairman, Education Institute
Cleveland Clinic Foundation
Cleveland, Ohio
Robert A. Sandhaus, MD, PhD
Professor of Medicine
Medical Director, AATD Program
National Jewish Health
Denver, Colorado
Michael J. Krowka, MD
Professor of Medicine
Vice Chairman
Division of Pulmonary and Critical Care Medicine
Mayo Clinic Transplant Center
Rochester, Minnesota
Jean Wall Bennett Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Head, Cleveland Clinic Respiratory Therapy
Chairman, Education Institute
Cleveland Clinic Foundation
Cleveland, Ohio
Robert A. Sandhaus, MD, PhDProfessor of Medicine
Medical Director, AATD Program
National Jewish Health
Denver, Colorado
Michael J. Krowka, MDProfessor of Medicine
Vice Chairman
Division of Pulmonary and Critical Care Medicine
Mayo Clinic Transplant Center
Rochester, Minnesota
DIME Editor
Dana Ravyn, PhD, MPH
Scientific Director
DIME
Chicago, Illinois
Target Audience
The target audience for this activity includes primary care physicians, pulmonologists, and other healthcare professionals interested in alpha-1 antitrypsin deficiency.
Activity Purpose
The purpose of this activity is to enhance knowledge and competence in physicians and other healthcare professionals who manage patients with alpha-1 antitrypsin deficiency to improve recognition and patient outcomes.
Statement of Need
Although alpha-1 antitrypsin (AAT) deficiency is one of the most common genetic life-threatening diseases worldwide and testing is convenient and inexpensive, it remains underrecognized and undertreated. There are an estimated 100,000 persons in the United States with AAT deficiency, but less than 10% have been diagnosed. The interval between onset of symptoms and diagnosis has been documented to be as much as 8.3 years, with patients seeing 3 or more physicians before obtaining a diagnosis of AAT deficiency. This delay in diagnosis is associated with an increased risk of mortality. Recognition of AAT deficiency can lead to beneficial interventions to increase survival and improve quality of life. Exercise, proper nutrition, and lifestyle modifications (e.g., smoking cessation, alterations in job settings to minimize occupational hazards) can improve well-being and lung function in patients with AAT deficiency. Augmentation therapy with human AAT has a demonstrated ability to reduce the rate of lung function loss, slow the rate of decline in the FEV1, and lower the rate of bronchial infection while being a generally safe and well-tolerated therapy. Moreover, cumulative mortality has been shown to decrease in those patients who have undergone augmentation therapy when compared with controls not receiving augmentation. Awareness and education can motivate healthcare providers to test for AAT deficiency, while enhancing knowledge and competence in the management of those with severe AAT deficiency provides opportunities to improve patient outcomes.
DISCLOSURE ATTESTATION
*DIME requires that all persons who were in a position to control or influence the content of this CME activity disclose all relevant financial relationships with any commercial interest. This information is used to: (1) determine whether a conflict exists, (2) resolve the conflict by initiating a content validation process, and (3) advise learners of this information.
FACULTY DISCLOSURES
Dr. James K. Stoller has consulted for Arriva Pharmaceuticals, CSL Behring, and Talecris Biotherapeutics Inc. He has received honoraria from Baxter International Inc., CSL Behring, Grifols, S.A., and Talecris Biotherapeutics Inc. Dr. Stoller has no off-label, experimental, and investigational uses to disclose.
Dr. Robert A. Sandhaus has done research for CSL Behring, Kamada, and Talecris Biotherapeutics Inc., and has consulted for Arriva Pharmaceuticals, Inc., and Kamada. He has also received honoraria from CSL Behring, Dey, L.P., and Talecris Biotherapeutics Inc. Dr. Sandhaus has no off-label, experimental, and investigational uses to disclose.
Dr. Michael J. Krowka has nothing to disclose.
DIME Editor
Dana Ravyn, PhD, MPH, has nothing to disclose.
DISCLOSURE POLICY STATEMENT
This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. DIME requires the speaker to disclose that a product is not labeled for the use under discussion. The provider's documentation of common practices that make the disclosure requirement known to faculty demonstrates compliance with ACCME guidelines.
DISCLAIMER
In accordance with DIME policies regarding financial and off-label disclosure, the learner is advised that this CME activity may contain references to off-label or unapproved uses of drugs or devices. The use of these agents outside currently approved labeling is considered experimental, and participants are advised to consult prescribing information for these products. This CME activity was planned and produced in accordance with ACCME Essential Areas and Policies.
This activity is funded through an educational grant from Talecris Biotherapeutics Inc. The activity content was developed independently by the contributing faculty or editors. The materials included in this activity have undergone peer review by the chairperson(s) or editor(s). All materials are included with the permission of the authors. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
ACCREDITATION STATEMENT
DIME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION
DIME designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 0.5 AMA PRA Category 1 Credits™. Statement of credit will be available to print from your user history page.
COURSE VIEWING REQUIREMENTS
Release Date: August 18, 2009
Expiration Date: August 31, 2010
COMMERCIAL SUPPORT
Funded by an educational grant from Talecris Biotherapeutics Inc.
This continuing medical education activity is sponsored by DIME.
www.DIMedEd.org
Dana Ravyn, PhD, MPH
Scientific Director
DIME
Chicago, Illinois
Target Audience
The target audience for this activity includes primary care physicians, pulmonologists, and other healthcare professionals interested in alpha-1 antitrypsin deficiency.
Activity Purpose
The purpose of this activity is to enhance knowledge and competence in physicians and other healthcare professionals who manage patients with alpha-1 antitrypsin deficiency to improve recognition and patient outcomes.
Statement of Need
Although alpha-1 antitrypsin (AAT) deficiency is one of the most common genetic life-threatening diseases worldwide and testing is convenient and inexpensive, it remains underrecognized and undertreated. There are an estimated 100,000 persons in the United States with AAT deficiency, but less than 10% have been diagnosed. The interval between onset of symptoms and diagnosis has been documented to be as much as 8.3 years, with patients seeing 3 or more physicians before obtaining a diagnosis of AAT deficiency. This delay in diagnosis is associated with an increased risk of mortality. Recognition of AAT deficiency can lead to beneficial interventions to increase survival and improve quality of life. Exercise, proper nutrition, and lifestyle modifications (e.g., smoking cessation, alterations in job settings to minimize occupational hazards) can improve well-being and lung function in patients with AAT deficiency. Augmentation therapy with human AAT has a demonstrated ability to reduce the rate of lung function loss, slow the rate of decline in the FEV1, and lower the rate of bronchial infection while being a generally safe and well-tolerated therapy. Moreover, cumulative mortality has been shown to decrease in those patients who have undergone augmentation therapy when compared with controls not receiving augmentation. Awareness and education can motivate healthcare providers to test for AAT deficiency, while enhancing knowledge and competence in the management of those with severe AAT deficiency provides opportunities to improve patient outcomes.
DISCLOSURE ATTESTATION
*DIME requires that all persons who were in a position to control or influence the content of this CME activity disclose all relevant financial relationships with any commercial interest. This information is used to: (1) determine whether a conflict exists, (2) resolve the conflict by initiating a content validation process, and (3) advise learners of this information.
FACULTY DISCLOSURES
Dr. James K. Stoller has consulted for Arriva Pharmaceuticals, CSL Behring, and Talecris Biotherapeutics Inc. He has received honoraria from Baxter International Inc., CSL Behring, Grifols, S.A., and Talecris Biotherapeutics Inc. Dr. Stoller has no off-label, experimental, and investigational uses to disclose.
Dr. Robert A. Sandhaus has done research for CSL Behring, Kamada, and Talecris Biotherapeutics Inc., and has consulted for Arriva Pharmaceuticals, Inc., and Kamada. He has also received honoraria from CSL Behring, Dey, L.P., and Talecris Biotherapeutics Inc. Dr. Sandhaus has no off-label, experimental, and investigational uses to disclose.
Dr. Michael J. Krowka has nothing to disclose.
DIME Editor
Dana Ravyn, PhD, MPH, has nothing to disclose.
DISCLOSURE POLICY STATEMENT
This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. DIME requires the speaker to disclose that a product is not labeled for the use under discussion. The provider's documentation of common practices that make the disclosure requirement known to faculty demonstrates compliance with ACCME guidelines.
DISCLAIMER
In accordance with DIME policies regarding financial and off-label disclosure, the learner is advised that this CME activity may contain references to off-label or unapproved uses of drugs or devices. The use of these agents outside currently approved labeling is considered experimental, and participants are advised to consult prescribing information for these products. This CME activity was planned and produced in accordance with ACCME Essential Areas and Policies.
This activity is funded through an educational grant from Talecris Biotherapeutics Inc. The activity content was developed independently by the contributing faculty or editors. The materials included in this activity have undergone peer review by the chairperson(s) or editor(s). All materials are included with the permission of the authors. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
ACCREDITATION STATEMENT
DIME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION
DIME designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 0.5 AMA PRA Category 1 Credits™. Statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the posttest and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 70% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the posttest and evaluation will receive a certificate of participation.
COURSE VIEWING REQUIREMENTS
| PC Internet Explorer (v6 or greater), or Firefox |
MAC Safari |
Release Date: August 18, 2009
Expiration Date: August 31, 2010
COMMERCIAL SUPPORT
Funded by an educational grant from Talecris Biotherapeutics Inc.
This continuing medical education activity is sponsored by DIME.
www.DIMedEd.org
